Asco 2023 – a role for immuno-oncology in ovarian cancer at last?
Astra’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Asco 2023 preview – Tigit lives again
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Asco 2023 – Commands leaves the door open for Geron
Full data from Reblozyl’s Commands study show limited activity in MDS patients without ringed sideroblasts – a boon for Geron.
Asco 2023 – Regeneron nips at Bristol’s heels in Lag3
Fianlimab continues to look like biopharma’s leading Lag3 asset, with activity in a new melanoma setting to boot.
Here come the PD-1 agonists
Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?
The waxing and waning of the speedy approval
As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?